Retatrutide needs Phase 3, larger tests of lasting benefit.

Early benefits need checking over more years

A possible medicine for weight and blood-sugar problems, retatrutide still needs testing. Here you'll learn what researchers found and what those findings leave unanswered. Eli Lilly was conducting Phase 3 tests as of 2026. These larger studies check benefit and harm before an approval request. Researchers want to know whether copying three hormones helps more than copying fewer.

Phase 2 means early tests of whether treatment helps people. Those studies weren't direct drug comparisons and can't settle which drug suits you. Even so, weight fell 24.2% on average over 48 weeks among people given the highest amount. Normal liver fat was reached by 86% in the liver study at week 24. Blood testing also showed better average sugar readings in type 2 diabetes. The reported change doesn't supply starting and ending readings.

Phase 3 must test whether benefits last and which harms emerge. Your future health depends on answers beyond the first months.

Three hormone effects may help with different parts of eating

Retatrutide is a 39-amino-acid chain; amino acids are small parts used to make proteins. LY3437943 is another study name for this drug. A hormone carries messages around your body. The drug copies GLP-1, GIP, and glucagon by attaching where cells receive those messages. That gives retatrutide ways to affect calorie use alongside changes in hunger and sugar, rather than depending only on reduced eating, though cell tests alone can't establish your lasting benefits.

GLP-1 helps you want less food and keeps meals in the stomach longer. Insulin release increases when blood sugar rises. Linking that release to sugar levels may reduce low-sugar risk compared with older drugs that release insulin regardless of need. Your other medicines can still add risk.

GIP helps release insulin after eating and changes how fat tissue handles fuel. GIP appears to add to GLP-1's hunger and insulin effects. The paired effects may help more than either alone. That remains something researchers need to test in people.

Glucagon helps you burn more calories while resting. The hormone also helps break apart fat in the liver for fuel ^[7]. Drugs copying GLP-1/GIP don't have that added effect. The possible benefit reaches beyond simply wanting less food.

Cells in a dish responded to retatrutide at all three attachment places ^[3]. The GIP effect was strongest; researchers kept the GLP-1 effect weaker on purpose. They sought help with insulin and fat without relying chiefly on the hunger effect. Those cell tests explain a design choice. They can't tell you how the same drug will affect your body over years.

The liver study measured a fall in stored fat

The liver study was small and didn't test whether scars healed. Fatty liver disease means too much fat has collected in your liver. Weight and blood-sugar problems are linked to the kind of disease studied here. You can read the liver and weight results together.

Just 98 people took part, all carrying excess weight without type 2 diabetes and with scans showing at least 10% fat in their livers, so the group was quite narrowly chosen. After 24 weeks, liver fat fell −42.9% with 1 milligram. With 4 milligrams, the fall was −57.0%; with 8 milligrams, −81.4%. With 12 milligrams, the fall was −82.4%. Each figure is a change in the fat present at the start. The placebo group, given shots without retatrutide, had a +0.3% change. At 12 milligrams, 86% reached normal liver fat, below 5%, at week 24. Fat fell −86.0% by 48 weeks ^[5].

Less stored fat isn't proof of healed liver scars.

A 2026 review examined 6 studies of drugs copying glucagon, including retatrutide ^[12]. Scans showed less liver fat, and tests linked to liver injury and scarring improved. Another review estimated the greatest falls in weight and average blood sugar with retatrutide ^[14]. The sugar finding was clear enough to link to treatment after allowing for chance. The weight estimate was less certain. Separate studies can't pick the best drug for you.

Reviews of the science offer possible reasons for the changes ^[7][13]. Glucagon helps your liver use stored fat as fuel. GLP-1/GIP effects reduce eating and fat elsewhere. The combined effects may remove more liver fat than either alone.

A 2025 review described unusually large weight and sugar changes for drugs tested in fatty liver disease ^[8]. Yet direct tests of liver tissue and scars were scarce. Advanced liver illness might also change how the drug moves through your body. Your liver's lasting health needs more evidence than a better scan.

Phase 2, early benefit tests, studied weight and type 2 diabetes

The weight study lasted months. This Phase 2 test, an early check of benefit, lasted 48 weeks and was published in 2023 ^[1]. Researchers studied 338 adults given weekly shots beneath skin. The amounts were 1/4/8/12 milligrams: one, four, eight, or twelve milligrams. At 48 weeks, weight fell −24.2% with 12 milligrams, against −2.1% with placebo, which contained none of the drug. Stomach trouble increased with the amount, though usually mild or moderate. The greatest pulse rise came at 24 weeks.

The diabetes follow-up was short. This type 2 diabetes Phase 2 test, another early check, lasted 36 weeks and was published in 2023 ^[2]. The 281 adults received rising weekly amounts within 0.5–12 milligrams. At 24 weeks, the test for average blood sugar improved with 12 milligrams. Placebo brought almost no sugar change. At 36 weeks, weight fell −16.94%, against −3.00% with placebo. Stomach complaints affected 35% and were mild or moderate. There were no severe low-sugar events or deaths.

The first test checked safety. Published in 2022 ^[4], the study involved 72 adults with type 2 diabetes. Weekly amounts rose within 0.5–12 milligrams over 12 weeks. Drug levels halved after about 6 days. At the highest amount, people lost −8.96 kilograms more than those given placebo. The minus sign marks extra loss beyond placebo. Researchers used a 90% range around the average extra loss. Such ranges would catch the true average nine times in ten if similar studies were repeated. At 3 milligrams, daily average blood sugar also fell. Safety findings supported further tests.

Retatrutide and tirzepatide still lack a published direct test

Different people and follow-up lengths prevent a fair drug comparison. In 2025, Moiz and colleagues reviewed 26 studies involving 15,491 adults ^[9]. Retatrutide at 12 milligrams showed 22.1% weight loss over 48 weeks. They used a 95% range around the estimated average, meaning such ranges would cover the true average ninety-five times in a hundred if similar studies were repeated. That concerns the group's average, not the spread of individual losses. Tirzepatide at 15 milligrams showed 17.8% loss over 72 weeks. Semaglutide at 2.4 milligrams showed 13.9% over 68 weeks. TRIUMPH aims to test both drugs directly.

Katsi and colleagues reviewed early studies in 2025 ^[6]. Those Phase 1/2 studies were early safety tests and early tests of benefit. The review described losses up to about 24% as a large advance over earlier hormone drugs. That can't decide your treatment.

Phase 3, larger tests, must check lasting benefits and harms

As of mid-2026, Eli Lilly's Phase 3 studies were still running. These larger tests must check benefits and harms before an approval request. You don't yet have their answers about lasting health. The work includes:

• TRIUMPH-1 and TRIUMPH-2: weight studies lasting 52+ weeks in larger groups.
• TRIUMPH-3: weight and blood-sugar changes in type 2 diabetes.
• Heart studies: checks for help or harm to the heart.
• Kidney studies: lasting kidney illness and heart safety.
• A further kidney safety study: more checks for kidney disease.

Researchers need to learn whether losses last and how much weight returns once treatment stops. They must check heart attacks, kidney safety, and whether liver scarring slows. GLP-1 drugs, which imitate a hormone involved in hunger, have shown weight returning after stopping.

A 2025 review described weight regain as a continuing problem ^[10]. A 2026 review described differing responses linked to genes, the instructions inherited in your cells, and your body's defenses ^[11]. Your immune system protects against threats, but may also make proteins that block this drug, which is one reason benefits in daily care may differ from those seen under study checks. Early weight loss doesn't settle your lasting benefit.

Reviews from 2024–2026 found gains in scans and blood tests

Abenavoli and colleagues, 2026 ^[11]. The liver findings are early, with little firm evidence about slowing scars. The review describes changes that may protect the liver and improve fuel use. Your liver could hold less fat without having healed scars.

Andonie and colleagues, 2026 ^[12]. The drugs came from separate studies, making a direct choice uncertain. Drugs copying glucagon improved fat scans and tests tied to liver injury and scarring. Resmetirom, a different liver drug, did better at easing liver inflammation without worsening scars.

Lu and colleagues, 2026 ^[13]. Their review explains possible GLP-1/GIP/glucagon effects on fat, inflammation, and scars. Those hormone names describe hunger, insulin, and fuel use. Possible reasons for improvement aren't proof of healing in you.

Abulehia and colleagues, 2026 ^[14]. Retatrutide had the largest estimated weight and sugar falls compared with placebo, the drug-free treatment. Only its sugar change was clear enough to make chance an unlikely cause. The weight estimate was less certain, even though people did lose weight. Another test drug, survodutide, ranked next for those estimated changes. A direct drug comparison is still needed.

You can find these retatrutide papers through the numbered links.